Skip to content

Enhancing Conservative Treatment for Urge Incontinence

Enhancing Conservative Treatment for Urge Incontinence

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00223821
Acronym
COMBO
Enrollment
166
Registered
2005-09-22
Start date
2003-09-30
Completion date
2009-12-31
Last updated
2013-12-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Urinary Incontinence

Keywords

Behavior Therapy, Behavioral Medicine, Behavioral Research, Behavioral Sciences, Combined Modality Therapy, Drug Therapy, Overactive bladder, Treatment Outcome, Urge incontinence, Urinary incontinence

Brief summary

The primary objective of this project is to evaluate whether enhancing drug therapy with components of behavioral training, including pelvic floor muscle rehabilitation, results in better outcomes than drug therapy alone for urge incontinence in community-dwelling women.

Detailed description

Urinary incontinence in women is a major problem with significant medical, psychological, and social consequences. Previous research on urge incontinence, a common form of incontinence, has demonstrated that behavioral and drug interventions are effective, but do not cure most patients. Thus there is a need to improve conservative treatment for urge incontinence in women. The primary objective of this project is to evaluate whether enhancing drug therapy with components of behavioral training, including pelvic floor muscle rehabilitation, results in better outcomes than drug therapy alone for urge incontinence in community-dwelling women. This project is a randomized controlled clinical trial. Sixty-four women with predominantly urge incontinence have been randomized. Stratification and blocked randomization procedures are used to assign a subject to 8 weeks of drug therapy alone or 8 weeks of drug therapy enhanced with components of behavioral training that can be administered in most any outpatient clinic. The drug therapy is extended release oxybutynin, a well-established pharmacologic agent with a state of the art drug delivery system that has the lowest rates of side-effect. The behavioral treatment is an innovative, comprehensive, behavioral training program, which includes pelvic floor muscle rehabilitation, teaching urge suppression and other skills to improve bladder control, and self-monitoring with bladder diaries. Bladder diaries completed by subjects before and after the treatment are used to calculate reduction in the frequency of incontinence. Secondary outcomes measures include a patient satisfaction questionnaire and three impact/quality of life measures (Incontinence Impact Questionnaire, Uro-Genital Distress Index, SF-12 Health Survey). The second objective of the study is to examine the cost-effectiveness of adding behavioral components to drug therapy. With the changing health care environment, there is increased concern with the costs of providing treatment. This project will compare the relative costs and value of combined intervention using the methods of cost-effectiveness analysis, the most widely adopted method for the economic evaluation of health interventions. The third objective of the study is to examine further the mechanisms by which these therapies reduce incontinence, including changes in bladder capacity, thresholds for bladder sensation, pelvic muscle strength, use of pelvic muscles in response to the sensation of urgency and frequency of urination. Pre-post changes in these parameters are measured to examine the effects of the treatment on these variables, and structural equation modeling will be used to examine whether changes in each of these measures are related to treatment outcome.

Interventions

DRUGOxybutynin chloride, extended-release, individually-titrated

Individually-titrated, extended-release oxybutynin chloride with management of side-effects.

BEHAVIORALBehavior Training

Behavioral training consists of teaching urge suppression strategies and pelvic floor muscle training.

Sponsors

US Department of Veterans Affairs
Lead SponsorFED

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
FEMALE
Age
19 Years to No maximum
Healthy volunteers
No

Inclusion criteria

Participants in this study were ambulatory, community-dwelling women (veterans and nonveterans) with persistent urge or predominantly urge incontinence. Participants must: 1. Be ambulatory. 2. Be able to come to the clinic for treatment. 3. Report urge incontinence. 4. Report incontinence occurring at least twice per week on average. 5. Report incontinence persisting for at least three months. 6. Not have received behavioral therapy in the University of Alabama at Birmingham (UAB) Continence Clinic or Department of Veterans Affairs (VA) Continence Clinic. 7. In the clinical interview, the subject must report involuntary loss of urine associated with a strong desire to void and that the condition has persisted for at least three months. 8. At least two urge accidents on the 7-day baseline bladder diary, and the number of urge accidents must exceed the number of other types of accidents. 9. On urodynamic evaluation, there must be cystometric evidence of bladder dysfunction, either: detrusor instability or maximal cystometric capacity is less than 400 ml.

Exclusion criteria

1. Continual leakage. 2. Urinary tract infection (defined as growth of greater than 10,000 colonies per ml of a urinary pathogen on urine culture). 3. Fecal impaction. 4. Uncontrolled metabolic problem. 5. Post-void residual volume \> 150 ml. 6. Hematuria on microscopic examination in the absence of infection. A urologic consultation will be recommended and enrollment will depend on agreement between the urologist and geriatrician (co-PI) that entry into treatment protocol is not contraindicated. 7. Severe uterine prolapse (prolapse reaching the vaginal introitus). 8. Decompensated congestive heart failure, diagnosed by history or physical exam. 9. Impaired mental status. (\<24 on Folstein's Mini-Mental State Exam). 10. Uncontrolled narrow angle glaucoma. 11. Gastric retention (by medical history). 12. Hypersensitivity to oxybutynin. 13. Current use of anticholinergic agents for detrusor instability. Subjects on these medications will be asked to discontinue them for the duration of the study. Evaluation will be delayed until the drug(s) have been discontinued for 2 weeks. 14. If on diuretic, dose stable for less than three months.

Design outcomes

Primary

MeasureTime frameDescription
Change in Incontinent Episodes Immediately Post-treatmentBaseline and immediately post-treatment - week 8Percent change from baseline in weekly frequency of incontinent episodes immediately post-treatment, derived from baseline and week 8 seven-day bladder diaries.

Secondary

MeasureTime frameDescription
Change in Incontinent Episodes at 12-month Follow-upBaseline and 12 months post-treatmentPercent change from baseline in weekly frequency of incontinent episodes at 12-months post-treatment, derived from baseline and 12-month seven-day bladder diaries

Countries

United States

Participant flow

Recruitment details

Participants were community-dwelling women with urge predominant incontinence recruited between July 2003 and January 2008.

Pre-assignment details

Of the 166 women enrolled, 58 were found to be ineligible on clinical evaluation, 44 withdrew, and 64 were randomized.

Participants by arm

ArmCount
Arm 1
drug therapy alone Extended release Oxybutynin Chloride : Individually-titrated, extended release oxybutynin chloride with management of side-effects.
32
Arm 2
drug therapy + behavioral training Extended release Oxybutynin Chloride : Individually-titrated, extended release oxybutynin chloride with management of side-effects. Behavior Training : Behavioral training consists of teaching urge suppression strategies and pelvic floor muscle training.
32
Total64

Baseline characteristics

CharacteristicArm 1Arm 2Total
Age Continuous59.3 years
STANDARD_DEVIATION 11.2
57.4 years
STANDARD_DEVIATION 12.6
58.4 years
STANDARD_DEVIATION 11.9
Ethnicity (NIH/OMB)
Hispanic or Latino
0 Participants0 Participants0 Participants
Ethnicity (NIH/OMB)
Not Hispanic or Latino
32 Participants32 Participants64 Participants
Ethnicity (NIH/OMB)
Unknown or Not Reported
0 Participants0 Participants0 Participants
Incontinence severity
Mild (less than 5 episodes/wk)
4 participant4 participant8 participant
Incontinence severity
Moderate (5-10 episodes/wk)
7 participant10 participant17 participant
Incontinence severity
Severe (> 10 episodes/wk)
21 participant18 participant39 participant
Incontinence type
missing
0 participants1 participants1 participants
Incontinence type
Mixed urge + stress
7 participants5 participants12 participants
Incontinence type
Urge only
25 participants26 participants51 participants
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Asian
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Black or African American
6 Participants14 Participants20 Participants
Race (NIH/OMB)
More than one race
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Unknown or Not Reported
0 Participants0 Participants0 Participants
Race (NIH/OMB)
White
26 Participants18 Participants44 Participants
Region of Enrollment
United States
32 participants32 participants64 participants
Sex: Female, Male
Female
32 Participants32 Participants64 Participants
Sex: Female, Male
Male
0 Participants0 Participants0 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
— / —— / —
other
Total, other adverse events
0 / 320 / 32
serious
Total, serious adverse events
0 / 320 / 32

Outcome results

Primary

Change in Incontinent Episodes Immediately Post-treatment

Percent change from baseline in weekly frequency of incontinent episodes immediately post-treatment, derived from baseline and week 8 seven-day bladder diaries.

Time frame: Baseline and immediately post-treatment - week 8

Population: Intention to treat

ArmMeasureValue (MEAN)Dispersion
Drug Therapy AloneChange in Incontinent Episodes Immediately Post-treatment-88.5 percentage changeStandard Deviation 24
Drug Therapy + Behavioral TrainingChange in Incontinent Episodes Immediately Post-treatment-78.3 percentage changeStandard Deviation 32.6
Comparison: The effectiveness of each intervention was calculated by comparing the weekly frequency of incontinent episodes (derived from seven-day bladder diaries) during baseline to that in the immediate post-intervention period (week 8). The primary analysis was based on intent-to-treat, in which post-treatment frequency of incontinence for non-completers was derived from the most recent week of diaries.p-value: 0.1695% CI: [-5.13, 25.54]ANCOVA
Secondary

Change in Incontinent Episodes at 12-month Follow-up

Percent change from baseline in weekly frequency of incontinent episodes at 12-months post-treatment, derived from baseline and 12-month seven-day bladder diaries

Time frame: Baseline and 12 months post-treatment

Population: Intention to treat

ArmMeasureValue (MEAN)Dispersion
Drug Therapy AloneChange in Incontinent Episodes at 12-month Follow-up-82.0 percent changeStandard Deviation 26.1
Drug Therapy + Behavioral TrainingChange in Incontinent Episodes at 12-month Follow-up-75.2 percent changeStandard Deviation 33.4
p-value: 0.3795% CI: [-10.73, 24.33]ANCOVA

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026